SCHEMBL8406844

SCHEMBL8406844

Cc1cccc(OC(C)C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.61
CYP1A2 P05177 1/20 0.56
GAA P10253 1/20 0.56
CYP2C9 P11712 1/20 0.56
PKM P14618 1/20 0.56
CYP2C19 P33261 1/20 0.56
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.51
ADORA3 P0DMS8 2/20 0.49
ADORA2A P29274 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
ACHE P22303 1/20 0.48
RECQL P46063 1/20 0.48
PPARG P37231 2/20 0.48
PPARA Q07869 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20832771 1.00 TDP1 (0.61) TDP1CYP1A2GAACYP2C9PKM
SCHEMBL30360591 1.00 TDP1 (0.61) TDP1CYP1A2GAACYP2C9PKM
SCHEMBL11189324 0.91 TDP1 (0.55) TDP1CYP1A2GAACYP2C9PKM
SCHEMBL30360621 0.84 LMNA (0.53) TDP1GAALMNATP53ADORA3
SCHEMBL28872457 0.84 LMNA (0.53) TDP1GAALMNATP53ADORA3
SCHEMBL16244402 0.84 LMNA (0.53) TDP1LMNATP53ADORA3ADORA2A
SCHEMBL6507757 0.82 TDP1 (0.61) TDP1CYP1A2GAACYP2C9PKM
SCHEMBL14122295 0.82 TP53 (0.52) LMNATP53ADORA3ADORA2AKMT2A
SCHEMBL14121601 0.82 TP53 (0.52) LMNATP53ADORA3ADORA2AKMT2A
SCHEMBL14121604 0.82 TP53 (0.52) LMNATP53ADORA3ADORA2AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109705060-B Preparation method of N- (2-morpholinyl-5-trifluoromethylphenyl) -2- (3-methylphenoxy) propionamide 华东理工大学 2023-04-14 CN claimed
CN-109705060-A A kind of preparation method of N- (2- morpholinyl -5- trifluoromethyl) -2- (3- methylphenoxy) propionamide 华东理工大学 2019-05-03 CN claimed
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-01-11 US disclosed
CN-109705060-B Preparation method of N- (2-morpholinyl-5-trifluoromethylphenyl) -2- (3-methylphenoxy) propionamide 华东理工大学 2023-04-14 CN disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 US disclosed
US-10744117-B2 PPARG modulators for the treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2020-08-18 US disclosed
CN-109705060-A A kind of preparation method of N- (2- morpholinyl -5- trifluoromethyl) -2- (3- methylphenoxy) propionamide 华东理工大学 2019-05-03 CN disclosed
US-20180369196-A1 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2018-12-27 US disclosed
US-10016394-B2 PPARG modulators for treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2018-07-10 US disclosed
US-20170035730-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2017-02-09 US disclosed
WO-2015161108-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS THE SCRIPPS RESEARCH INSTITUTE (US) 2015-10-22 WO disclosed
WO-2012170561-A1 N-BENZYLINDOLE MODULATORS OF PPARG THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) 2012-12-13 WO disclosed
US-20120309769-A1 N-BENZYLINDOLE MODULATORS OF PPARG SCRIPPS RESEARCH INSTITUTE, THE (US) 2012-12-06 US disclosed
CN-100503600-C Heterocyclic pesticides BAYER CROPSCIENCE AG (DE) 2009-06-24 CN disclosed
CN-101070317-A Heterocyclic derivatives, composition containing same and method for pests control FMC CORP (US) 2007-11-14 CN disclosed
CN-1692108-A Heterocyclic pesticides FMC CORP (US) 2005-11-02 CN disclosed
US-5928912-A EFFICIENT BIOSYNTHESIS BASF AKTIENGESELLSCHAFT (DE) 1999-07-27 US disclosed
US-4252961-A Intermediates of and process for making 3-[5-[1-(2-, 3-, or 4-methyl, or ethyl or isopropylphenoxy)alkyl, alkynyl, alkenyl, or haloalkyl]-1,3,4-thiadiazol-2-yl]-4-hydroxy-1-methyl-2-imidazolidinones PPG INDUSTRIES, INC. (US) 1981-02-24 US disclosed
US-4218236-A PREEMERGENCE AND POSTEMERGENCE HERBICIDES PPG INDUSTRIES, INC. (US) 1980-08-19 US disclosed
US-3935193-A ANTIBIOTICS TOYO JOZO KABUSHIKI KAISHA (JA) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170035730-A1 PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS PPARG, PPARA, PPARD TDP1 2673/4885CYP1A2 3613/4885GAA 3582/4885
US-10016394-B2 PPARG modulators for treatment of osteoporosis PPARG, PPARA, PPARD TDP1 2673/4885CYP1A2 3613/4885GAA 3582/4885
US-20120309769-A1 N-BENZYLINDOLE MODULATORS OF PPARG PPARG, CDK5R1, CDK5 TDP1 3560/4885CYP1A2 2946/4885GAA 3460/4885
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD TDP1 2686/4885CYP1A2 3409/4885GAA 3259/4885
US-20180369196-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD TDP1 2686/4885CYP1A2 3409/4885GAA 3259/4885
US-10744117-B2 PPARG modulators for the treatment of osteoporosis PPARG, PPARA, PPARD TDP1 2686/4885CYP1A2 3409/4885GAA 3259/4885
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD TDP1 2686/4885CYP1A2 3409/4885GAA 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.